Opening the book…
This historical account follows FDA inspection observations, a company recall statement, and later FDA testimony about McNeil’s 2010 recall. The events are documented; the
explanation of their connection to variation is a teaching analysis.
From April 19 to April 30, 2010, FDA investigators examined McNeil Consumer Healthcare’s Fort Washington, Pennsylvania, facility. It made medicines for infants and children. A caregiver measuring a dose depended on the medicine having the stated strength and meeting its other quality requirements. Inside the facility, investigators were examining the manufacturing controls meant to support that expectation.
The investigators recorded concerns about evaluating manufacturing changes, mixing, and controls for processes associated with variability in finished medicine. They also identified gaps in tracking and trending products, components, and complaints. These findings appeared in the Form FDA 483 issued April 30. The form records inspection observations, rather than a final agency determination of compliance.
The concern soon reached families’ medicine cabinets. In a May 1 statement, Johnson & Johnson reported that McNeil had announced a voluntary recall the previous night. Some recalled infants’ and children’s products might contain more active ingredient than specified; other concerns involved inactive ingredients and particles. The company stated that adverse medical events were not the basis for the recall.
On September 30, FDA Principal Deputy Commissioner Joshua Sharfstein described the response to Congress. He linked the Fort Washington recall to potency variability, particles, and possible microbial contamination. McNeil’s reported corrective plan included stopping manufacturing, renovating the facility, improving quality systems, and obtaining outside expert review. These were reported actions and plans, not proof in the testimony that remediation was complete.
Sharfstein also reported a limit on the evidence of harm. FDA’s investigation of adverse-event reports concerning the recalled products had not, overall, established a direct link to a serious adverse event, including death. That finding did not make the quality concerns acceptable or establish that no harm could have occurred. Manufacturing problems still required action.
The case connects to this chapter through the need to investigate variability, review manufacturing changes, and assess affected product. The public account does not supply enough time-ordered process data to classify every issue as common-cause or special-cause variation. It also does not establish that a single control chart would have prevented the recall. The lesson is to build evidence about the process rather than rely on isolated passing samples.
This page titled 6.6: A children’s medicine recall brings variation into focus was last modified on Sat, 07 Nov 2026 00:50:28 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.